Log In
BCIQ
Print this Print this
 

Zepatier, elbasvir/grazoprevir (MK-5172/MK-8742)

Also known as: grazoprevir/elbasvir

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionFixed-dose oral combination of grazoprevir, an HCV NS3/4A protease inhibitor, and elbasvir, an HCV NS5A protein inhibitor
Molecular Target HCV NS3/4A protease complex ; HCV NS5A protein
Mechanism of ActionHCV non-structural protein 5A inhibitor; HCV NS3 protease inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV genotype 1 infection in patients with chronic kidney disease (CKD); Treat chronic HCV genotype 1 infection in patients with end-stage renal disease (ESRD) on hemodialysis; Treat chronic HCV genotype 1, 2 and 3 infection; Treat chronic HCV genotype 1, 4 or 6 and HIV co-infection; Treat chronic HCV genotype 4 infection; Treat chronic HCV genotypes 1, 4 or 6 infection; Treat chronic HCV infection; Treat HCV infection
Regulatory Designation U.S. - Breakthrough Therapy (Treat chronic HCV genotype 4 infection);
U.S. - Breakthrough Therapy (Treat chronic HCV genotype 1 infection in patients with end-stage renal disease (ESRD) on hemodialysis);
U.S. - Priority Review (Treat chronic HCV genotypes 1, 4 or 6 infection);
EU - Accelerated Assessment (Treat chronic HCV genotypes 1, 4 or 6 infection)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today